Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: insights from the AVERT trial
Background The use of direct oral anticoagulants (DOACs) in obese patients is uncertain. It
is unclear if body mass index (BMI) affects the safety and efficacy of DOACs for the primary
prevention of venous thromboembolism (VTE) in high-risk ambulatory patients with cancer.
We sought to determine the outcomes associated with the use of apixaban for the primary
prevention of cancer-associated VTE according to BMI. Methods The randomized, double-
blinded, placebo-controlled AVERT trial evaluated apixaban thromboprophylaxis in …
is unclear if body mass index (BMI) affects the safety and efficacy of DOACs for the primary
prevention of venous thromboembolism (VTE) in high-risk ambulatory patients with cancer.
We sought to determine the outcomes associated with the use of apixaban for the primary
prevention of cancer-associated VTE according to BMI. Methods The randomized, double-
blinded, placebo-controlled AVERT trial evaluated apixaban thromboprophylaxis in …
以上显示的是最相近的搜索结果。 查看全部搜索结果